688062 Stock Overview
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of biological products in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Mabwell (Shanghai) Bioscience Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥24.55 |
| 52 Week High | CN¥37.00 |
| 52 Week Low | CN¥19.90 |
| Beta | 1.1 |
| 11 Month Change | 2.12% |
| 3 Month Change | 5.36% |
| 1 Year Change | -7.36% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0.20% |
Recent News & Updates
Shareholder Returns
| 688062 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 5.8% | -2.5% | -2.1% |
| 1Y | -7.4% | -14.2% | 6.7% |
Return vs Industry: 688062 exceeded the CN Biotechs industry which returned -12.4% over the past year.
Return vs Market: 688062 underperformed the CN Market which returned 8.3% over the past year.
Price Volatility
| 688062 volatility | |
|---|---|
| 688062 Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in CN Market | 12.4% |
| 10% least volatile stocks in CN Market | 5.5% |
Stable Share Price: 688062 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688062's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 1,402 | Datao Liu | www.mabwell.com |
Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of biological products in China and internationally. The company offers its products for auto-immune, oncology, ophthalmologic, and infectious diseases, as well as metabolic disorders, etc. It offers JUNMAIKANG, an autoimmune Adalimumab injection. The company’s oncology products pipeline includes 9MW2821 and 6MW3211, which are in phase II of clinical trial; 9MW2921, 9MW3811, and 7MW3711, which are in phase I clinical trials; 9MW0321; and 8MW0511, which is in phase III clinical trial.
Mabwell (Shanghai) Bioscience Co., Ltd. Fundamentals Summary
| 688062 fundamental statistics | |
|---|---|
| Market cap | CN¥9.81b |
| Earnings (TTM) | -CN¥1.07b |
| Revenue (TTM) | CN¥169.42m |
57.9x
P/S Ratio-9.1x
P/E RatioIs 688062 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688062 income statement (TTM) | |
|---|---|
| Revenue | CN¥169.42m |
| Cost of Revenue | CN¥21.09m |
| Gross Profit | CN¥148.33m |
| Other Expenses | CN¥1.22b |
| Earnings | -CN¥1.07b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.69 |
| Gross Margin | 87.55% |
| Net Profit Margin | -634.07% |
| Debt/Equity Ratio | 106.8% |
How did 688062 perform over the long term?
See historical performance and comparison